ReviewLeukemia2003
Transforming growth factor-beta signaling in normal and malignant hematopoiesis.
Review in Leukemia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis.Nature communications · 2026Article
- Loss of SMAD1 in acute myeloid leukemia withFrontiers in oncology · 2024Article
- PKC-ζ mediated reduction of the extracellular vesicles-associated TGF-β1 overcomes radiotherapy resistance in breast cancer.Breast cancer research : BCR · 2023Article
- Review
- Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment.Cancers · 2022Review
- Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia.Stem cells (Dayton, Ohio) · 2021Article
- Reducing TGF-β1 cooperated with StemRegenin 1 promoted the expansion ex vivo of cord blood CD34Cell proliferation · 2021Article
- Loss of TG-Interacting Factor 1 decreases survival in mouse models of myeloid leukaemia.Journal of cellular and molecular medicine · 2020Article
- The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.International journal of molecular sciences · 2020Article
- Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia.Oncology letters · 2019Article
- The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGFβ signaling in zebrafish.Blood advances · 2019Article
- The role of TGFβ in hematopoiesis and myeloid disorders.Leukemia · 2019Review
- Association between Altered Expression and Genetic Variations of Transforming Growth Factor β-Smad Pathway with Chronic Myeloid Leukemia.International journal of hematology-oncology and stem cell research · 2018Article
- Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules.Cold Spring Harbor perspectives in biology · 2017Review
- Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia.Oncotarget · 2017Article
- The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation.Oncotarget · 2016Article
- Transforming Growth Factor β Drives Hemogenic Endothelium Programming and the Transition to Hematopoietic Stem Cells.Developmental cell · 2016Article
- Cell intrinsic and extrinsic regulation of leukemia cell metabolism.International journal of hematology · 2016Review
- The proto-oncogenic protein TAL1 controls TGF-β1 signaling through interaction with SMAD3.Biochimie open · 2016Article
- TGF-β signaling and its role in the regulation of hematopoietic stem cells.Systems and synthetic biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Transforming growth factor-beta (TGF-beta) is perhaps the most potent endogenous negative regulator of hematopoiesis. The intracellular signaling events mediating the effects of TGF-beta are multiple, involving extensive crosstalk between Smad-dependent and MAP-kinase-dependent pathways. We are only beginning to understand the importance of the balance between these cascades as a determinant of the response to TGF-beta, and have yet to determine the roles that disruption in TGF-beta signaling pathways might play in leukemogenesis. This review summarizes current knowledge regarding the function of TGF-beta in normal and malignant hematopoiesis. The principal observations made by gene targeting studies in mice are reviewed, with an emphasis on how a disruption of this pathway in vivo can affect blood cell development and immune homeostasis. We overview genetic alterations that lead to impaired TGF-beta signaling in hematopoietic neoplasms, including the suppression of Smad-dependent transcriptional responses by oncoproteins such as Tax and Evi-1, and fusion proteins such as AML1/ETO. We also consider mutations in genes encoding components of the core cell cycle machinery, such as p27(Kip1) and p15(INK4A), and emphasize their impact on the ability of TGF-beta to induce G1 arrest. The implications of these observations are discussed, and opinions regarding important directions for future research on TGF-beta in hematopoiesis are provided.
Indexed as
Identifiers
12970772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.